Suppr超能文献

表现为少量蛋白尿或无蛋白尿的 IgA 肾病的长期预后。

Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria.

机构信息

Department of Nephrology, Hospital 12 de Octubre, Avenida de Córdoba s/n, Madrid, Spain.

出版信息

J Am Soc Nephrol. 2012 Oct;23(10):1753-60. doi: 10.1681/ASN.2012010063. Epub 2012 Sep 6.

Abstract

The long-term outcome of patients with IgA nephropathy who present with normal renal function, microscopic hematuria, and minimal or no proteinuria is not well described. Here, we studied 141 Caucasian patients with biopsy-proven IgA nephropathy who had minor abnormalities at presentation and a median follow-up of 108 months. None of the patients received corticosteroids or immunosuppressants. We reviewed renal biopsies using the Oxford classification criteria. In this sample, 46 (32%) patients had mesangial proliferation, whereas endocapillary proliferation, focal glomerulosclerosis, and tubulointerstitial abnormalities were uncommon. Serum creatinine increases >50% and >100% were observed in five (3.5%) patients and one (0.7%) patient, respectively; no patients developed ESRD. After 10, 15, and 20 years, 96.7%, 91.9%, and 91.9% of patients maintained serum creatinine values less than a 50% increase, respectively. Using Cox proportional hazards regression, the presence of segmental glomerulosclerosis was the only factor that significantly associated with a >50% increase in serum creatinine. Clinical remission occurred in 53 (37.5%) patients after a median of 48 months. Proteinuria>0.5 and >1.0 g/24 h developed in 21 (14.9%) and 6 (4.2%) patients, respectively. Median proteinuria at the end of follow-up was 0.1 g/24 h, with 41 (29.1%) patients having no proteinuria. At presentation, 23 (16.3%) patients were hypertensive compared with 30 (21.3%) patients at the end of follow-up; 59 (41.8%) patients were treated with renin-angiotensin blockers because of hypertension or increasing proteinuria. In summary, the long-term prognosis for Caucasian patients with IgA nephropathy who present with minor urinary abnormalities and normal renal function is excellent.

摘要

患有 IgA 肾病的患者,其临床表现为肾功能正常、镜下血尿、微量或无蛋白尿,其长期预后尚不清楚。在这里,我们研究了 141 例经活检证实的 IgA 肾病患者,这些患者在发病时存在轻微异常,中位随访时间为 108 个月。这些患者均未接受皮质激素或免疫抑制剂治疗。我们使用牛津分类标准对肾活检标本进行了回顾性分析。在本样本中,46(32%)例患者存在系膜增生,而内皮下增生、局灶性肾小球硬化和肾小管间质病变则不常见。5 例(3.5%)患者的血清肌酐升高超过 50%,1 例(0.7%)患者的血清肌酐升高超过 100%;无患者进展至终末期肾病。10、15 和 20 年后,分别有 96.7%、91.9%和 91.9%的患者的血清肌酐值增加小于 50%。使用 Cox 比例风险回归分析,节段性肾小球硬化是唯一与血清肌酐增加超过 50%显著相关的因素。53 例(37.5%)患者在中位时间为 48 个月时达到临床缓解。21 例(14.9%)和 6 例(4.2%)患者的蛋白尿分别超过 0.5 g/24 h 和 1.0 g/24 h。随访结束时的平均蛋白尿为 0.1 g/24 h,41 例(29.1%)患者无蛋白尿。在发病时,23 例(16.3%)患者为高血压,而在随访结束时,30 例(21.3%)患者为高血压;由于高血压或蛋白尿增加,59 例(41.8%)患者接受了肾素-血管紧张素阻滞剂治疗。总之,临床表现为轻微尿路异常和肾功能正常的白人 IgA 肾病患者的长期预后良好。

相似文献

2
IgA nephropathy with minimal change disease.IgA 肾病伴微小病变病。
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1033-9. doi: 10.2215/CJN.11951113. Epub 2014 Apr 10.

引用本文的文献

5
Emerging perspectives in the management of IgA nephropathy: a comprehensive review.IgA肾病管理的新观点:全面综述
Porto Biomed J. 2024 Nov 14;9(6):264. doi: 10.1097/j.pbj.0000000000000264. eCollection 2024 Nov-Dec.
6
Immunoglobulin A Nephropathy: A Review.免疫球蛋白A肾病:综述
Perm J. 2024 Dec 16;28(4):87-94. doi: 10.7812/TPP/24.089. Epub 2024 Nov 5.
10
Contemporary review of IgA nephropathy.IgA 肾病的当代综述。
Front Immunol. 2024 Aug 12;15:1436923. doi: 10.3389/fimmu.2024.1436923. eCollection 2024.

本文引用的文献

1
Current therapy for IgA nephropathy.IgA 肾病的当前治疗方法。
J Am Soc Nephrol. 2011 Oct;22(10):1785-94. doi: 10.1681/ASN.2011030221. Epub 2011 Sep 8.
3
Predicting the risk for dialysis or death in IgA nephropathy.预测 IgA 肾病患者发生透析或死亡的风险。
J Am Soc Nephrol. 2011 Apr;22(4):752-61. doi: 10.1681/ASN.2010040355. Epub 2011 Jan 21.
10
Remission of proteinuria improves prognosis in IgA nephropathy.蛋白尿缓解可改善IgA肾病的预后。
J Am Soc Nephrol. 2007 Dec;18(12):3177-83. doi: 10.1681/ASN.2007050526. Epub 2007 Oct 31.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验